TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People’s Republic of China. More Details
Adequate balance sheet and fair value.
Share Price & News
How has TOT BIOPHARM International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1875 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1875's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1875 underperformed the Hong Kong Biotechs industry which returned 42.8% over the past year.
Return vs Market: 1875 underperformed the Hong Kong Market which returned 21.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is TOT BIOPHARM International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StTOT BIOPHARM International (HKG:1875) Shareholders Booked A 11% Gain In The Last Year
2 months ago | Simply Wall StAn Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
4 months ago | Simply Wall StHere's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Is TOT BIOPHARM International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1875 (HK$4.37) is trading below our estimate of fair value (HK$9.53)
Significantly Below Fair Value: 1875 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1875 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 1875 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1875's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1875 is good value based on its PB Ratio (3.7x) compared to the HK Biotechs industry average (4.1x).
How is TOT BIOPHARM International forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1875's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if 1875's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1875's revenue (34.7% per year) is forecast to grow faster than the Hong Kong market (12.6% per year).
High Growth Revenue: 1875's revenue (34.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1875's Return on Equity is forecast to be high in 3 years time (26.6%)
How has TOT BIOPHARM International performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 1875 is currently unprofitable.
Growing Profit Margin: 1875 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1875's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1875's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1875 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43.1%).
Return on Equity
High ROE: 1875 has a negative Return on Equity (-49.54%), as it is currently unprofitable.
How is TOT BIOPHARM International's financial position?
Financial Position Analysis
Short Term Liabilities: 1875's short term assets (CN¥249.2M) exceed its short term liabilities (CN¥52.7M).
Long Term Liabilities: 1875's short term assets (CN¥249.2M) exceed its long term liabilities (CN¥6.1M).
Debt to Equity History and Analysis
Debt Level: 1875 is debt free.
Reducing Debt: 1875 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1875 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 1875 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.8% each year
What is TOT BIOPHARM International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1875's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1875's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1875's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1875's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1875's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jun Liu (52 yo)
Dr. Jun Liu serves as Chief Executive Officer at TOT BIOPHARM International Company Limited since October 15, 2020 and serves as its Executive Director since October 26, 2018. Dr. Liu serves as Chief Scien...
Experienced Management: 1875's management team is considered experienced (3 years average tenure).
Experienced Board: 1875's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.
TOT BIOPHARM International Company Limited's company bio, employee growth, exchange listings and data sources
- Name: TOT BIOPHARM International Company Limited
- Ticker: 1875
- Exchange: SEHK
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$2.629b
- Shares outstanding: 601.53m
- Website: https://www.totbiopharm.com
Number of Employees
- TOT BIOPHARM International Company Limited
- No. 120 Changyang Street
- Suzhou Industrial Park
- Jiangsu Province
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People’s Republic of China. Its pri...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 10:19|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.